Two thirds of breast cancers, referred to as estrogen receptor positive , contain high levels of cells which contain estrogen receptors. These tumors tend to grow less aggressively than estrogen receptor unfavorable tumors. Young patients with breast malignancy are currently advised to undergo courses of chemotherapy as well as removal of the tumor and/or entire breasts. A research team of the European Organisation for Analysis and Treatment of Tumor selected sufferers from four EORTC-trials which were coordinated by Professor C.J.H. Van de Velde from the Leiden University Medical Center, to study the result of chemotherapy in young women. The research team discovered that ER+ patients, while they benefited from their chemotherapy treatment, did not survive at higher rates than ER – individuals.Renal function continues to be evaluated by two actions in the extension study, estimated glomerular filtration rate and 24-hour urine proteins. Preliminary data show that eGFR offers remained steady out to 3-4 years for all subjects continuing in the expansion study and the average annual rate of transformation in eGFR in subjects identified as responders to migalastat HCl, excluding hyperfiltrators, was +1.6 mL/min/1.73m2.